These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 15614963)

  • 21. Once-daily quadruple-drug therapy with adefovir dipivoxil, Lamivudine, Didanosine, and efavirenz in treatment-naive human immunodeficiency virus type 1-infected patients.
    Skowron G; Kuritzkes DR; Thompson MA; Squires KE; Goodwin SD; Dusak BA; Tolson JM; Stevens M; Yuen GJ; Rooney JF;
    J Infect Dis; 2002 Oct; 186(7):1028-33. PubMed ID: 12232846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New expanded access drugs for use in combination therapy.
    Notes Undergr; 1998; (No 37):suppl 1-2. PubMed ID: 11365823
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug interactions. Super pills-the treatments of the future?
    TreatmentUpdate; 2006; 18(3):2-3. PubMed ID: 17209236
    [No Abstract]   [Full Text] [Related]  

  • 24. Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz.
    Maggiolo F; Migliorino M; Maserati R; Pan A; Rizzi M; Provettoni G; Rizzi L; Suter F;
    Antivir Ther; 2001 Dec; 6(4):249-53. PubMed ID: 11878406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tenofovir and didanosine: a dangerous liaison.
    Waters L; Maitland D; Moyle GJ
    AIDS Read; 2005 Aug; 15(8):403-6, 413. PubMed ID: 16110555
    [No Abstract]   [Full Text] [Related]  

  • 26. Antiretroviral therapy for previously untreated HIV-1-infected adults: 2NN, or just one?
    Carr A
    Lancet; 2004 Apr; 363(9417):1248-50. PubMed ID: 15094265
    [No Abstract]   [Full Text] [Related]  

  • 27. FDA notifications. Generic efavirenz/emtricitabine/fenofovir has tentative approval.
    AIDS Alert; 2009 Oct; 24(10):119-20. PubMed ID: 20034141
    [No Abstract]   [Full Text] [Related]  

  • 28. [Lipid profile and body fat--significant "side effect" of antiretroviral therapy. Tenofovir: favorable profile of adverse effects].
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():83. PubMed ID: 15011603
    [No Abstract]   [Full Text] [Related]  

  • 29. Neuropsychiatric adverse events after switching from an antiretroviral regimen containing efavirenz without tenofovir to an efavirenz regimen containing tenofovir: a report of nine cases.
    Allavena C; Le Moal G; Michau C; Chiffoleau A; Raffi F
    Antivir Ther; 2006; 11(2):263-5. PubMed ID: 16640107
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial.
    Molina JM; Journot V; Morand-Joubert L; Yéni P; Rozenbaum W; Rancinan C; Fournier S; Morlat P; Palmer P; Dupont B; Goujard C; Dellamonica P; Collin F; Poizot-Martin I; Chene G;
    J Infect Dis; 2005 Mar; 191(6):830-9. PubMed ID: 15717256
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [3 years' data of tenofovir. Confirmed as a valuable building block].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():30-1. PubMed ID: 15373042
    [No Abstract]   [Full Text] [Related]  

  • 32. Severe toxicity associated with the combination of tenofovir and didanosine: case report and review.
    Masiá M; Gutiérrez F; Padilla S; Ramos JM; Pascual J
    Int J STD AIDS; 2005 Sep; 16(9):646-8. PubMed ID: 16176639
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy.
    Moyle G; Higgs C; Teague A; Mandalia S; Nelson M; Johnson M; Fisher M; Gazzard B
    Antivir Ther; 2006; 11(1):73-8. PubMed ID: 16518962
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults.
    Martínez E; Milinkovic A; de Lazzari E; Ravasi G; Blanco JL; Larrousse M; Mallolas J; García F; Miró JM; Gatell JM
    Lancet; 2004 Jul 3-9; 364(9428):65-7. PubMed ID: 15234858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The continuing evolution of HIV therapy.
    Boyle BA
    AIDS Read; 2003 Dec; 13(12):576-8, 582. PubMed ID: 14959692
    [No Abstract]   [Full Text] [Related]  

  • 36. Sustiva granted full FDA approval.
    AIDS Read; 2000 Mar; 10(3):147. PubMed ID: 10798886
    [No Abstract]   [Full Text] [Related]  

  • 37. Recent FDA approvals and changes.
    AIDS Patient Care STDS; 2010 May; 24(5):342. PubMed ID: 20482468
    [No Abstract]   [Full Text] [Related]  

  • 38. [A "once daily" drug that with proven effectiveness. Efavirenz has successful outcome also in direct comparisons].
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():12-3. PubMed ID: 15011576
    [No Abstract]   [Full Text] [Related]  

  • 39. Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.
    Elzi L; Marzolini C; Furrer H; Ledergerber B; Cavassini M; Hirschel B; Vernazza P; Bernasconi E; Weber R; Battegay M;
    Arch Intern Med; 2010 Jan; 170(1):57-65. PubMed ID: 20065200
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir.
    Barreiro P; Soriano V
    J Antimicrob Chemother; 2006 May; 57(5):806-9. PubMed ID: 16531427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.